Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03031938 · ClinicalTrials.gov registry record · Phase 3
Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
NCT03031938 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 4 participants.
The verdict
NCT03031938, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
Study Summary
A4091065 is a multicenter, prospective, cohort study with enhance physical an neurodevelopmental surveillance to characterize the outcomes related to the development of infants up to the age of 15 months who were potentially exposed to tanezumab, placebo or comparator via maternal exposure or in utero in any tanezumb study.
Interventions
- DRUG Investigational medical product (IMP) administered in parent study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-11-03 |
| Est. Completion | 2020-06-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03031938
The ClinicalTrials.gov registry entry for NCT03031938 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Investigational medical product (IMP) administered in parent study is the first listed.
NCT03031938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03031938 about?
NCT03031938 is a clinical study titled "Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies". A4091065 is a multicenter, prospective, cohort study with enhance physical an neurodevelopmental surveillance to characterize the outcomes related to the development of infants up to the age of 15 months who were potentially exposed to tanezumab, placebo or comparator via maternal exposure or in ute...
What is the current status of trial NCT03031938?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2017-11-03. Estimated completion is 2020-06-04.
What interventions are being tested in trial NCT03031938?
The interventions under investigation include: Investigational medical product (IMP) administered in parent study (DRUG).
Who is sponsoring clinical trial NCT03031938?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.